Top Suppliers:I want be here


141206-42-0

141206-42-0 structure
141206-42-0 structure
  • Name: Lucerastat
  • Chemical Name: (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
  • CAS Number: 141206-42-0
  • Molecular Formula: C10H21NO4
  • Molecular Weight: 219.27800
  • Catalog: Research Areas Metabolic Disease
  • Create Date: 2016-03-05 00:47:05
  • Modify Date: 2024-01-05 14:35:22
  • Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].

Name (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
Synonyms NB-DGJ
UNII-GVS3YDM418
Lucerastat
N-Butyl-DGJ
N-Bu-DGJ
Description Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
Related Catalog
In Vitro Fabry patient-derived fibroblasts with the genotypes R301G (residual -GalA activity; 20%) R220X (<3%) and W162X (<1%). Cell Viability Assay[2]. Cell Line: Fabry patient-derived fibroblasts with the genotypes R301G (residual -GalA activity; 20%) R220X (<3%) and W162X (<1%). Concentration: Incubation Time: 9 days. Result: Dose-dependently inhibited GCS, reducing glucosylceramide and increasing sphingomyelin.
In Vivo Lucerastat (1200 mg/kg/day food admix), a GCS inhibitor, reduces Gb3 in the absence of residual -GalA activity[2]. Animal Model: Fabry mice (Gla-/0 and Gla-/-, n = 5 or 6 for each gender)[2]. Dosage: 1200 mg/kg/day food admix. Administration: Food admix for 20 weeks. Result: Reduced lipid storage in two major organs affected by FD: mean Gb3 in the kidneys (-33%, p<0.01). and α-galactose- terminated glycosphingolipids in the dorsal root ganglia (-48%, p<0.05). In the liver of the Fabry mice, mean glucosylceramide (GlcCer (24:0)) was reduced (-59%, p<0.001) in addition to Gb3 (24:1) (-37%, p<0.05) demonstrating substrate reduction through GCS inhibition.
References

[1]. Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.

[2]. R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.

Molecular Formula C10H21NO4
Molecular Weight 219.27800
Exact Mass 219.14700
PSA 84.16000
Hazard Codes Xn